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Unrestrained receptor tyrosine kinase (RTK) sig-
naling and epigenetic deregulation are root causes
of tumorigenesis. We establish linkage between
these processes by demonstrating that aberrant
RTK signaling unleashed by oncogenic HRasG12V or
loss of negative feedback through Sprouty gene
deletion remodels histone modifications associated
with active typical and super-enhancers. However,
although both lesions disrupt the Ras-Erk axis,
the expression programs, enhancer signatures,
and transcription factor networks modulated upon
HRasG12V transformation or Sprouty deletion are
largely distinct. Oncogenic HRasG12V elevates his-
tone 3 lysine 27 acetylation (H3K27ac) levels at en-
hancers near the transcription factor Gata4 and the
kinase Prkcb, as well as their expression levels. We
show that Gata4 is necessary for the aberrant gene
expression and H3K27ac marking at enhancers,
and Prkcb is required for the oncogenic effects of
HRasG12V-driven cells. Taken together, our findings
demonstrate that dynamic reprogramming of the
cellular enhancer landscape is amajor effect of onco-
genic RTK signaling.INTRODUCTION
Enhancers are collections of DNA motifs that govern gene ex-
pression at long distances from transcriptional start sites, es-
tablishing cellular identity. Enhancers contain binding sites for
sequence-specific transcription factors (TFs) and associated
cofactors that assemble in a combinatorial manner to promote
cell-type-specific gene expression patterns (Spitz and Furlong,
2012). Enhancer dysfunction contributes to disease progres-
sion and occurs through mutation of enhancer regulatory fac-
tors, such as P300 and CBP in Rubinstein-Taybi syndrome,
as well as through changes in the underlying enhancer DNA1300 Cell Reports 12, 1300–1313, August 25, 2015 ª2015 The Authosequence, such as rearrangement of the IgH enhancer aber-
rantly activating c-MYC in Burkitt’s lymphoma (Smith and Shi-
latifard, 2014). This underscores the importance of understand-
ing how enhancers function in normal development and
disease.
Histone modification signatures can be used to classify en-
hancers. Primed and poised enhancers are identified by the
presence of histone 3 lysine 4 mono-methylation (H3K4me1)
and lack of histone 3 lysine 4 tri-methylation (H3K4me3),
whereas active enhancers are marked with histone 3 lysine 27
acetylation (H3K27ac) and H3K4me1 (Creyghton et al., 2010;
Heintzman et al., 2007; Rada-Iglesias et al., 2011). The deposi-
tion of H3K4me1 by MLL2 and MLL3, and H3K27ac by p300
and CBP, is dynamically regulated (Brown et al., 2014; Herz
et al., 2012; Kaikkonen et al., 2013; Ostuni et al., 2013; Tie
et al., 2009). For example, upon activation of NF-kB signaling,
primed enhancers transition to an active state by gaining
H3K27ac at regions with pre-existing H3K4me1. At a subset
of unmodified regions, inducible deposition of H3K4me1 and
H3K27ac occurs at latent or de novo enhancers (Kaikkonen
et al., 2013; Ostuni et al., 2013). Super-enhancers (SEs), which
are similar to locus control regions or stretch enhancers, are an
additional class of regulatory regions that contain clusters of
typical enhancers (TEs) and extend over several kilobases of
the genome (Smith and Shilatifard, 2014). SEs are disproportion-
ately marked with H3K27ac, are preferentially occupied by
enhancer-associated factors including bromodomain and ex-
tra-terminal domain (BET) coactivator proteins such as BRD4,
and control transcriptional regulators and fate-determining
genes in normal and malignant cells (Love´n et al., 2013; Whyte
et al., 2013). During the inflammatory response, SEs are rapidly
modified, as NF-kB directs BRD4 redistribution at SEs (Brown
et al., 2014). Although controlled pathway activation triggers
dynamic chromatin remodeling at enhancers, how oncogenic
signaling globally remodels enhancers has not been extensively
studied.
Although stimuli can elicit chromatin remodeling and TF as-
sembly at enhancers and promoters, the rapid activation of sig-
naling pathways precedes transcriptional responses. Receptor
tyrosine kinase (RTK) signaling pathways are one example of
a critical signaling network that is required for normalrs
development and is misregulated in disease. Fibroblast growth
factor (FGF)-mediated RTK activation triggers the Ras-ERK
signaling cascade, dictating whether a cell will divide, survive,
migrate, or differentiate (Turner and Grose, 2010). Mutations in
signaling effectors including RAS, BRAF, and PIK3CA, which
are among the most commonly mutated genes in cancer,
unleash critical RTK pathways including the Ras-ERK and
PI3K-AKT signaling cascades to promote tumorigenesis (Kan-
doth et al., 2013; Stephen et al., 2014). RTK signaling cascades
are also regulated by feedback loops that promote or limit
pathway activation. Sprouty genes (Spry1,2,3,4) encode RTK
feedback inhibitors required for development of the kidney, in-
ner ear, and other organs (Basson et al., 2005; Edwin et al.,
2009; Shim et al., 2005). Spry proteins primarily silence the
Ras-ERK pathway while also antagonizing the PI3K-AKT and
PLCg-PKC pathways (Akbulut et al., 2010; Hacohen et al.,
1998; Schutzman and Martin, 2012). Spry proteins have tumor
suppressor activity, and their expression levels are commonly
downregulated in cancer, leading to aberrant amplification of
RTK pathways, while their re-expression inhibits malignant
growth (Masoumi-Moghaddam et al., 2014). As such, it
is important to understand how unrestrained RTK signaling
mediated by mutant oncogenes or Spry disruption coor-
dinates changes in gene expression to promote malignant
transformation.
The Ras-ERK signaling axis in part regulates gene expression
through control of activating and repressive epigenetic mecha-
nisms. Active ERK1/2 directly binds DNA, controls RNA poly-
merase II, and works in concert with TFs such as ELK1 to
modulate gene expression (Go¨ke et al., 2013; Hu et al., 2009;
Tee et al., 2014). ERK1/2 indirectly impinges on chromatin by
controlling the activity of MSK1/2, which is responsible for his-
tone 3 serine 10 and serine 28 phosphorylation (H3S10ph and
H3S28ph), and p300 (Chen et al., 2007; Soloaga et al., 2003).
The Ras-Raf axis also activates the INK4A-ARF locus through
upregulation of the histone demethylase JMJD3, leading to
loss of histone 3 lysine 27 tri-methylation (H3K27me3) (Agger
et al., 2009; Barradas et al., 2009). These examples of the inter-
action between RTK signaling and chromatin modifications,
and their importance in tumorigenesis, led us to investigate
whether unrestrained RTK signaling driven by loss of feedback
regulation or mutant oncogene expression reprograms
enhancer-associated chromatin modifications. In this study,
we found that chronic Ras-Erk signaling mediated by Spry
loss leads to inappropriate gene activation, which correlates
with dynamic changes in H3K27ac at SEs and TEs. Constitutive
HRasG12V, KRasG12V, or BRafV600E activation also leads to aber-
rant H3K27ac marking at SEs and TEs. However, the deregu-
lated enhancers, target genes, and TF networks affected by
oncogenic activation and loss of feedback regulation largely
differ. Using the deregulated HRasG12V enhancer chromatin
signature, we identified Gata4 as a key deregulated transcrip-
tional regulator and Prkcb as a critical downstream kinase
mediating the aberrant gene expression and oncogenic effects
of HRasG12V-transformed cells, respectively. Our work sug-
gests that unrestrained RTK activation modulates gene expres-
sion and contributes to malignant transformation through
enhancer deregulation.CellRESULTS
Spry Loss Persistently Activates Erk Signaling and
Deregulates Gene Expression
To assess the consequences of Spry1,2,4 loss on Ras-Erk sig-
naling and gene expression, we compared immortalized mouse
embryonic fibroblasts (MEFs) with wild-type Spry1,2,4 expres-
sion and genetically matched cells with Spry1,2,4 knocked out.
This model was created by transducing Spry1,2,4flox/flox MEFs
with either a control adenovirus empty vector (EV) (Spry1,2,4
wild-type MEFs, referred to as Spry124fl/fl) or an adenovirus
expressing Cre to delete Spry1,2,4 (Spry1,2,4 deficient
MEFs, referred to as Spry124/) (Akbulut et al., 2010) (Fig-
ure S1A). We found that Spry124/ MEFs exhibited elevated
active, phosphorylated Erk at baseline in unsynchronized and
serum-starved states relative to Spry124fl/fl MEFs (Figure 1A).
Spry124/ MEFs also displayed elevated Erk activation 15–
60 min after FGF treatment, which persisted for 240 min, a
time point at which Erk activation returned to baseline levels
in Spry124fl/fl MEFs. These molecular differences correlated
with phenotypic characteristics of Spry124/ MEFs, including
more rapid proliferation in low-FGF conditions and increased
cell-cycle entry in response to FGF after serum deprivation (Fig-
ures 1B andS1B). Consistent with previous data, our results indi-
cate that Spry loss amplifies FGF-mediated Ras-Erk signaling
(Hacohen et al., 1998; Shim et al., 2005).
To identify specific genes that may underlie the effects
observed upon Spry loss, we performed RNA-sequencing
(RNA-seq) comparing Spry124fl/fl and Spry124/ MEFs. Given
the increased baseline Erk activation in Spry124/ MEFs, we
first identified the differentially expressed genes in the unsyn-
chronized states of Spry124fl/fl and Spry124/ MEFs (Table
S1). Ingenuity Pathway Analysis (IPA) revealed that these de-
regulated genes are involved in cancer and cardiovascular
disease and in cellular movement, morphology, and growth
(Figure S1C). Gene set enrichment analysis (GSEA) also re-
vealed that these deregulated genes are associated with
breast cancer, signaling pathways, and chromatin regulators
including PRC2 and MLL, suggesting that epigenetic deregula-
tion is a consequence of persistent signaling upon Spry loss
(Figure S1D).
To examine the signal-dependent transcriptional response in
these cells, we identified the FGF-responsive genes inSpry124fl/fl
MEFs and queried how theywere regulated inSpry124/MEFs.
In general, FGF-induced Spry124fl/fl genes were elevated in
Spry124/ MEFs in the unsynchronized and starved states,
consistent with basal pathway activation prior to FGF treatment
(Figure 1C; Table S1). We subsequently identified the FGF-
responsive genes that weremodulated in Spry124/MEFs (Fig-
ure 1D; Table S1). By contrast, FGF-induced Spry124/ genes
displayed significantly elevated expression levels in all cellular
states in Spry124/ MEFs. However, in both analyses, FGF-
repressed Spry124fl/fl and Spry124/ genes were largely over-
lapping in each comparison (Figures 1C and 1D). Therefore,
we focused on Spry124/ target genes that displayed both
elevated baseline and FGF-induced activation. Many of these
deregulated factors promote cellular migration (Itgb3, Fgf2,
Mmp13, and Serpinb2) and inflammation (Ccl2, Ptpn22, andReports 12, 1300–1313, August 25, 2015 ª2015 The Authors 1301
Figure 1. Chronic Erk Signaling Is Required for the Aberrant Gene Expression upon Spry Loss
(A) Immunoblot analysis of Spry124fl/fl and Spry124/MEFs that were freely growing (Unsync), serum starved (Starve), or serum starved and treated with FGF
over the time course indicated.
(B) Cell counts of Spry124fl/fl and Spry124/ MEFs cultured in the presence of FGF.
(C and D) RNA-seq analysis of Spry124fl/fl and Spry124/ MEFs under unsynchronized (U), starved (S), and FGF-treated (F) states. Heatmaps and boxplots
depict the significantly differentially expressed genes comparing Spry124fl/fl (C) and Spry124/ (D) MEFs in starved and FGF-treated conditions.
(E) Relative mRNA levels of Spry124/ target genes upon treatment of Spry124/MEFs with DMSO or PD0325901. mRNA levels of Spry124fl/fl MEFs treated
with DMSO are shown as a baseline reference.
(legend continued on next page)
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Sema7a). These sevenSpry124/ target genesdisplayed little to
no activation in Spry124fl/fl MEFs and were selected as a repre-
sentative panel of Spry124/ target genes for further assess-
ment (Figure S1E). Treatment of Spry124/ MEFs with a MEK
inhibitor, PD0325901 (Barrett et al., 2008), led to a dose-depen-
dent reduction inErk activation, and reducedbaseline expression
of five out of seven Spry124/ target genes tested to Spry124fl/fl
levels, indicating their dependence on Erk signaling (Figures 1E
and S1F). We also noted that a number of Spry124/ targets,
including Ccl2 and Fgf2, are Stat3 target genes (Yu et al.,
2009), suggesting that Stat3, an oncogenic TF activated by
RTK signaling, may be aberrantly activated upon Spry loss.
Accordingly, Spry124/ MEFs displayed elevated constitutive
phosphorylation of Stat3 tyrosine 705 and enhanced FGF-
induced phosphorylation of Stat3 serine 727 (Figure S1G).
Furthermore, Stat3 knockdown reduced the expression of all
seven Spry124/ target genes tested (Figures 1F and S1H).
Collectively, these data indicate that a transcriptional program
activated bySpry loss is driven by persistent Erk signaling and re-
quires Stat3 activation.
Spry LossDeregulates ChromatinMarking at Enhancers
To explore the consequences of persistent Erk signaling on
histone modifications associated with gene activation, we
performed chromatin immunoprecipitation (ChIP) followed by
next-generation sequencing (ChIP-seq) for the enhancer marks,
H3K4me1 and H3K27ac, and the active promoter mark,
H3K4me3. To identify TEs and SEs in each dataset, enhancer
regions were rank ordered based on the extent of H3K27ac
enrichment (Love´n et al., 2013) (Figure S2A; Table S4). The
median length and signal of H3K27ac at SEs is an order of
magnitude greater than TEs. SEs accounted for 14%–21% of
the H3K27ac signal (Figure S2B). Comparing Spry124fl/fl and
Spry124/ MEFs in unsynchronized, starved, or FGF-treated
states, we observed significant gains and losses in H3K27ac at
TEs and SEs (Figures 2A and S2C). The absolute change in
H3K27ac signal between Spry124fl/fl and Spry124/ MEFs
was significantly greater at SEs than TEs (Figure 2B). Further-
more, gain or loss of an SE in Spry124/ MEFs had a signifi-
cantly greater effect on gene expression than did changes at
TEs (Figure 2C). This suggests that chromatin changes at SEs
mediated the transcriptional effects of unrestrained signaling
upon Spry loss. We therefore focused on the SE signatures
and examined the sequences at gained Spry124/ SEs. This
analysis revealed significant enrichment of binding sites for
TFs such as NFIA/B (p < 106), ETS family members such as
ETV1 (p < 0.001), NF-kB2 (p < 0.005), and STAT3 (p < 0.005)
in Spry124/ MEFs (Figure 2D; Table S6). This finding is con-
sistent with the aberrant activation of NF-kB and Stat3 in
Spry124/ MEFs, the requirement of Stat3 for expression
Spry124/ targets, and the known role of NF-kB and STAT fac-
tors in enhancer remodeling (Brown et al., 2014; Ostuni et al.,
2013) (Figures 1F, S1G, and S2D).(F) Relative mRNA levels of Spry124/ target genes upon treatment of Spry124
n = 3 for (A)–(F). In (A), a representative biological replicate is shown. In (B), (E), and
replicate per condition is shown in the heatmap, and the replicates are averaged in
(F) and Wilcoxon rank sum test in (C) and (D); *p < 0.05.
CellWe also examined whether enhancers were remodeled after
FGF treatment (Figure 2A). Hierarchical clustering analyses of
the SE signatures highlighted the high reproducibility among
the biological replicates and demonstrated that the Spry124fl/fl
and Spry124/ SE signatures clustered separately with moder-
ate changes across each cellular state (Figure 2E; Table S3).
Baseline changes in SEs were largely maintained upon starva-
tion and FGF treatment. For example, the oncogenic Hoxa clus-
ter scored as an SE and displayed elevated H3K27ac enrichment
in the presence or absence of FGF in Spry124/ MEFs, which
correlated with elevated expression of Hoxa3-5 and H3K4me3
promoter enrichment (Figure 2F; Table S1). Similarly, a broad re-
gion upstream of the inflammatory cytokine, Ccl2, displayed
elevated H3K27ac enrichment in Spry124/MEFs and reached
SE levels in most conditions, correlating with elevated expres-
sion of Ccl2 and the presence of H3K4me3 at its promoter (Fig-
ures S1E and S2E). Although SEs were largely unresponsive
to FGF treatment, there were significant changes at TEs associ-
ated with Spry124/ target genes (Figures 2A and S2A). For
example, in Spry124/MEFs, a TE downstream of Sema7a ex-
hibited increased H3K27ac in the unsynchronized and starved
states, which was further elevated upon FGF treatment. Again,
these differences correlated with elevated Sema7a expression
and increased H3K4me3 at its promoter (Figures S1E and
S2E). These data indicate that Spry loss leads to significant
changes in H3K27ac at critical enhancers in all cellular states.
Abrogating Erk Signaling Diminishes H3K27ac at
Enhancers, while Oncogenic Ras and Raf Promote
H3K27ac at Enhancers
Next, we testedwhether chromatinmodifications at SEs and TEs
were maintained after inhibiting aberrant Erk signaling. Treat-
ment of Spry124/MEFs with PD0325901 significantly reduced
H3K27ac levels at sites associated with Ccl2, Sema7a, and
Mmp13 and decreased expression of these genes (Figures 1E
and 3A). However, H3K4me1 was maintained at these sites,
indicating that Erk signaling activates these primed enhancers
by directing the deposition of H3K27ac (Figure 3B). Since Erk
signaling was required to maintain H3K27ac, we predicted
that BET bromodomain proteins and p300/CBP, which re-
cognize and deposit H3K27ac, respectively, are necessary for
the aberrant activation of Spry124/ target genes. Accordingly,
treatment ofSpry124/MEFswith the BET bromodomain inhib-
itor, JQ1, which prevents association of BRD4 with TEs and SEs
of oncogenes to inhibit cancer cell growth (Filippakopoulos et al.,
2010; Love´n et al., 2013), significantly reduced the elevated
baseline and FGF-mediated expression of all seven Spry124/
target genes tested to Spry124fl/fl levels (Figure S3A). In addition,
treatment of Spry124/ MEFs with the p300/CBP inhibitor,
C646 (Bowers et al., 2010), significantly reduced the expression
of four out of seven Spry124/ target genes tested upon serum
deprivation and significantly diminished FGF-mediated gene
activation to Spry124fl/fl levels (Figure S3B). Collectively, our/ MEFs with control or Stat3 small interfering RNAs (siRNAs).
(F), the values depict themean + SD of biological replicates. In (C) and (D), each
the boxplots. The p values were calculated by a two-tailed t test in (B), (E), and
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Figure 2. Spry Loss Globally Reprograms Enhancer-Associated Chromatin Modifications
(A) Table summarizing the number of H3K27ac defined enhancers significantly modulated between Spry124fl/fl and Spry124/ MEFs in the indicated com-
parisons.
(B) Boxplot of the absolute change in H3K27ac density between Spry124fl/fl and Spry124/ MEFs at TEs and SEs.
(C) Boxplot of RNA-seq expression for genes proximal to TEs and SEs that were gained, unchanged, or lost in Spry124/ MEFs upon comparison between
Spry124fl/fl and Spry124/ MEFs under the indicated conditions.
(legend continued on next page)
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Figure 3. Inhibiting Erk Signaling De-
creases H3K27ac at Enhancers, while
Oncogenic Activation of the Ras-Raf Axis
Promotes H3K27ac at Enhancers
(A and B) ChIP-qPCR for H3K27ac (A) and
H3K4me1 (B) at Ccl2, Sema7a, and Mmp13
enhancer (labeled E) and control (labeled C)
regions upon treatment of Spry124/ MEFs
with DMSO or PD0325901. A schematic of primer
regions is shown, which correspond to enriched
Spry124/ enhancer sites identified using
ChIP-seq.
(C and D) ChIP-qPCR for H3K27ac (C) and
H3K4me1 (D) at Ccl2 and Sema7a enhancer sites
in the indicated MEFs. A schematic of the primer
locations is shown in Figure 3A.
n = 3 for (A)–(D). In (A)–(D), the values depict the
mean + SD of biological replicates. The p values
were calculated by a two-tailed t test; *p < 0.05.data indicate that aberrant deposition of H3K27ac at enhancers
requires persistent Ras-Erk signaling and that BET bromodo-
main proteins and p300/CBP are necessary for aberrant gene
activation upon Spry loss.
To test the idea that Spry loss would resemble the effects of
oncogenes that constitutively activate Ras-ERK and/or PI3K-
AKT, we stably transduced Spry124fl/fl MEFs with an EV control
or a panel of mutant oncogenes (EGFRL858R, PIK3CAH1047R,
KRasG12V, HRasG12V, and BRafV600E) and surveyed the resulting
expression and chromatin status of Spry124/ target genes.(D) Bar plot of the ratio of TFmotif density at gained Spry124/ FGF SEs in the indicated comparison (p < 0.05
change > 1.5. The fold change ranking of select TFs are indicated.
(E) Hierarchical clustering analysis of H3K27ac-defined SE regions in the indicated MEFs. Each biological re
(F) UCSC genome browser view of H3K27ac, H3K4me1, and H3K4me3 ChIP-seq binding density at the Hoxa
the indicated culture conditions. H3K27ac binding density at an adjusted scale is depicted in the box.
n = 2 for (A)–(F). In (A)–(D) and (F), a representative biological replicate is shown. The p values were calculate
Cell Reports 12, 1300–1313,Spry124/ MEFs transduced with an
EV served as a positive control. As ex-
pected, these oncogenes modulated
Ras-Erk and PI3K-Akt signaling (Fig-
ure S3C). KRasG12V, HRasG12V, and
BRafV600E significantly activated all seven
Spry124/ target genes tested (Fig-
ure S3D). Accordingly, KRasG12V,
HRasG12V, and BRafV600E significantly
increased H3K27ac levels at Spry124/
activated enhancers (Figures 3C and
S4A). The changes in enhancer marking
were largely limited to H3K27ac, as a sig-
nificant increase in H3K4me1 was only
observed at the Mmp13 enhancer (Fig-
ures 3D and S4B). These changes also
appeared to be specifically mediated by
Ras-Erk signaling. EGFRL858R and PIK3-
CAH1047R, which preferentially activated
Akt, did not stimulate changes in the
expression or H3K27ac levels at
Spry124/ target genes. These data
suggest that, although oncogenic Ras and Raf modulate
H3K27ac at shared subsets of Spry124/ enhancers, onco-
genes that primarily activate AKT may mediate their effects on
cell fate and gene expression through other sets of enhancers.
HRasG12V Transformation Modulates the Enhancer
Landscape
To determine the overlap of genes deregulated upon Spry loss
and those modulated by oncogenes, we performed RNA-seq
to identify genes differentially expressed in KRasG12V, HRasG12V,). Colored bars represent TFs with p < 0.05 and fold
plicate (rep) is displayed.
cluster in Spry124fl/fl and Spry124/MEFs under
d by a two-tailed t test; *p < 0.05.
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Figure 4. HRasG12V Promotes Global Changes in Chromatin Marking at Enhancers
(A and B) Heatmaps from RNA-seq analyses representing the significantly differentially expressed genes comparing Spry124fl/fl EV and Spry124/ EV MEFs (A)
or Spry124fl/fl EV and HRasG12V MEFs (B).
(C) Pie charts displaying H3K27ac signal at TEs and SEs upon comparison between Spry124fl/fl EV and HRasG12V MEFs.
(D) Table summarizing the number of H3K27ac defined enhancers significantly modulated between Spry124fl/fl EV and HRasG12V MEFs.
(E) Boxplot of the absolute change in H3K27ac density between Spry124fl/fl EV and HRasG12V MEFs at TEs and SEs.
(F) Boxplot of RNA-seq expression for genes proximal to TEs and SEs that were gained, unchanged, or lost in HRasG12V MEFs upon comparison between
Spry124fl/fl EV and HRasG12V MEFs.
(legend continued on next page)
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BRafV600E, and Spry124/ EV MEFs, compared to Spry124fl/fl
EV MEFs (Table S2). Surprisingly, the expression pattern of
genes modulated in Spry124/ EV MEFs was largely different
from those altered by KRasG12V, HRasG12V, or BRafV600E (Fig-
ure 4A). There was a high degree of overlap of genes deregulated
in response to KRasG12V, HRasG12V, and BRafV600E (for example,
KRasG12V targets overlapped with 94% of HRasG12V and 59% of
BRafV600E targets), with each of these gene sets having relatively
small overlap with Spry124/ EV target genes (Spry124/ EV
targets overlapped with 23% of KRasG12V, 34% of HRasG12V,
and 19% of BRafV600E targets) (Figure 4B; Table S2). We noted
a core set of 290 deregulated target genes that overlapped in
all datasets, which include the validated Spry124/ target
genes (Figure S4C). However, IPA revealed that many of the
same top classes of genes, such as cancer-associated genes,
and pathways, such as cellular movement and proliferation,
were shared among the oncogenic Ras, Raf, and Spry124/
gene sets (Figure S4D). This suggests that despite the differ-
ences in target genes affected, all four lesions affected common
core processes.
The differences in gene expression patterns upon Spry loss
and oncogene gain, led us to investigate the genome-wide con-
sequences of oncogenic mutations of the Ras-Raf axis on
enhancer marking. We performed ChIP-seq for H3K27ac,
H3K4me1, and H3K4me3, comparing Spry124fl/fl EV and
HRasG12V MEFs due to the potent effect of this oncogene on
gene expression and H3K27ac at Spry124/ activated en-
hancers (Figures 3C and S3D). Comparison of Spry124fl/fl EV
and HRasG12V MEFs revealed that HRasG12V transformation
significantly remodeled SEs and TEs (Figures 4C, 4D, S4E,
and S4F; Table S5). Consistent with ChIP-qPCR, HRasG12V
transformation modified TEs of shared Spry124/ target genes
including Sema7a (Figures 3C and S5A). However, the absolute
change in H3K27ac signal between Spry124fl/fl EV and HRasG12V
MEFs was significantly greater at SEs than TEs (Figure 4E).
Furthermore, genes that gained SEs upon HRasG12V trans-
formation had significantly increased expression levels, com-
pared to genes that gained only TEs (Figure 4F). This result
suggests that chromatin changes at SEs generated changes in
gene expression upon HRasG12V transformation. For example,
HRasG12V transformation resulted in significantly elevated
H3K27ac levels at regions associated with the proteoglycan
Dcn, the glycolate oxidase Hao1, and the kinase Prkcb, corre-
lating with their elevated expression levels (Figures 4G, S5B,
and S7A). We selected these factors as a representative set of
HRasG12V target genes with deregulated SEs for further assess-
ment, and we focused on the SE signatures in the subsequent
analyses. Collectively, these data demonstrate that HRasG12V
globally remodels enhancer marking.
Next, we compared SEs remodeled upon Spry loss and
HRasG12V transformation, as well as the TF networks deployed
by these lesions. Hierarchical clustering analyses revealed that
the HRasG12V SE signature was distinct from the Spry124fl/fl(G) UCSC genome browser view of H3K27ac, H3K4me1, and H3K4me3 ChIP-s
HRasG12V MEFs. H3K27ac binding density at an adjusted scale is depicted in th
n = 3 for (A) and (B); n = 2 for (C)–(G). In (A) and (B), each biological replicate is sho
calculated by a two-tailed t test; *p < 0.05.
CellEV, Spry124fl/fl, and Spry124/ SE signatures, with only small
subsets of SEs found in common (Figure 2E). By examining the
SE sequences in these cell lines, we identified the top core reg-
ulatory TF network that is likely to bind and activate gene expres-
sion in each dataset (Figure 5A). ETS1was identified as a core TF
in both the Spry124/ FGF and HRasG12V networks, consistent
with the role of ETS factors as mediators of Ras-ERK signaling
(Charlot et al., 2010). However, there were significant differences
in the TF networks upon Spry loss or HRasG12V transformation.
For example, NF-kB1 and MEF2A were identified as core
Spry124/ FGF TFs, while GATA4 and MEIS2 were identified
as core HRasG12V TFs. We also observed significant differences
in TF binding sites enriched at activated SEs upon comparison of
Spry124/ FGF and HRasG12V MEFs (Figure 5B; Table S6). In
particular, we observed enrichment of binding sites for ARNT
(p < 0.01) and GATA4 (p < 0.001) upon HRasG12V transformation,
while binding sites for HOXA1-3 (p < 0.0001) were overrepre-
sented upon Spry loss. To potentially explain the differences in
gene expression upon Spry loss and HRasG12V transformation,
we examined the levels of phosphotyrosine species in these
cells. Spry124/ EV MEFs displayed increased baseline inten-
sity of a 60-kDa band and a unique 150- to 185-kDa FGF-
induced band (Figure S5C). The larger band may represent
phosphorylated FGFR, indicating that Spry loss may impact re-
ceptor activation at levels above Ras. There were also differ-
ences in the intensity of activated Erk and Akt in Spry124/
EV MEFs (Figure S3C). Collectively, our data suggest that differ-
ences in the expression profiles and SE signatures upon Spry
loss and HRasG12V transformation may be due to quantitative
and qualitative changes in the activated signaling molecules
leading to modulation of different TF networks.
Gata4 Is Required for H3K27ac Marking at Enhancers
To identify TFs responsible for the expression and SE signatures
uponHRasG12V transformation, we identified TF binding sites en-
riched at activated HRasG12V SEs (Figure 6A; Table S6). Signifi-
cant enrichment of binding sites for TFs such as TWIST1 (p <
0.01) was detected upon HRasG12V transformation, consistent
with the known role of oncogenic Ras in regulating and cooper-
atingwith Twist1 in oncogenesis (DeCraene and Berx, 2013).We
also noted significant enrichment of binding sites for GATA4 (p <
0.001) and identified GATA4 as a core HRasG12V TF (Figures 5A
and 6A; Table S6). Furthermore, in HRasG12VMEFs, we observed
elevatedGata4 expression and amarked increase in H3K27ac at
a broad TE upstream of Gata4, indicating that Gata4 may
mediate the oncogenic Ras program (Figures 6B and S7A).
Gata4, which was not expressed to any significant level in
Spry124fl/fl MEFs, encodes a TF required for heart development,
and Gata4 mutations cause cardiac dysfunction (Garg et al.,
2003). Gata4 knockdown significantly reduced the expression
of all four HRasG12V target genes and six out of sevenSpry124/
target genes tested (Figures 6C and S6A). Gata4 knockdown led
to a significant reduction in H3K27ac, but not H3K4me1, ateq binding density at the Dcn (left) and Prkcb (right) loci in Spry124fl/fl EV and
e box.
wn. In (C)–(G), a representative biological replicate is shown. The p values were
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Figure 5. Spry Loss and Oncogenic
HRasG12V Modify Distinct TF Networks
(A) The top-ranking regulatory TF network identi-
fied at SEs in Spry124fl/fl FGF, Spry124/ FGF,
Spry124fl/fl EV, and Spry124fl/fl HRasG12V MEFs.
Each TF depicted represents a node in the
network.
(B) Bar plot of the ratio of TF motif density at
gained HRasG12V SEs in the indicated comparison
(p < 0.05). Colored bars represent TFs with p <
0.05 and fold change > 1.5. The fold change
ranking of select TFs are indicated.
n = 2 for (A) and (B). In (A) and (B), a representative
biological replicate is shown.enhancers (Figures 6D, 6E, and S6B). Consistent with the known
role of Gata4 as a pioneer factor at enhancers (Cirillo et al., 2002),
our data indicate that Gata4 is necessary for maintaining the
aberrant H3K27acmarking and gene expression upon HRasG12V
transformation. Although Stat3 binding sites were not enriched
at activated HRasG12V SEs, a Stat3 expression signature was de-
tected in the HRasG12V RNA-seq datasets (Figure S6C). Stat3
knockdown significantly reduced the expression of all four
HRasG12V target genes and six out of seven Spry124/ target
genes tested, indicating that Stat3 is also required for aberrant
gene activation (Figures S6D and S6E). Together, our data indi-
cate that HRasG12V-driven modulation of H3K27ac at enhancers
is dependent on Gata4 and Stat3.1308 Cell Reports 12, 1300–1313, August 25, 2015 ª2015 The AuthorsHRasG12V Enhancer Signature
Identifies Prkcb as a Key
Downstream Target Gene
The enhancer dysfunction due to
HRasG12V transformation led us to inves-
tigate whether chemical inhibition of
chromatin regulators or target genes
with aberrantly marked enhancers could
relieve the oncogenic effects of Ras.
Consistent with our observations in
Spry124/MEFs, treatment of HRasG12V
MEFs with PD0325901 or JQ1 signifi-
cantly reduced the expression of all four
HRasG12V and all seven Spry124/
target genes tested to Spry124fl/fl EV
levels, indicating their dependence on
Erk signaling and BET bromodomain ac-
tivity (Figure S7A). Accordingly, JQ1
treatment significantly diminished the
clonogenicity of HRasG12V MEFs (Fig-
ure S7B). JQ1 treatment reduced the
viability of HRasG12V MEFs, although
Spry124fl/fl EV MEFs were also sensitive
to inhibition by JQ1 alone. However,
a moderate synergistic effect was
observed in HRasG12V MEFs upon co-
treatment of PD0325901 and JQ1 at
doses of 0.1–0.5 mM (Figure S7C). C646
treatment alone also significantly re-
duced the viability of HRasG12V MEFs,while combinations of C646 and PD0325901 did not reveal a
synergistic effect on cell viability (Figure S7D). Our data indicate
that BET bromodomain proteins are necessary for the aberrant
gene expression, clonogenicity, and viability HRasG12V-trans-
formed cells.
Finally, we explored whether enhancer signaturesmight reveal
dependencies of HRasG12V-transformed cells. In particular, the
Prkcb locus had dramatically elevated H3K27ac levels upon
HRasG12V transformation, correlating with significant overex-
pression (Figures 4G and S7A). Prkcb is frequently amplified in
many malignancies and encodes a kinase that is considered a
potential therapeutic target in cancer, diabetes, and heart dis-
ease (Mochly-Rosen et al., 2012). We hypothesized that
Figure 6. Gata4 Is Required for HRasG12V Expression Programs and H3K27ac Marking at Enhancers
(A) Bar plot of the ratio of TF motif density at gained HRasG12V SEs in the indicated comparison (p < 0.05). Colored bars represent TFs with p < 0.05 and fold
change > 1.5. The fold change ranking of select TFs are indicated.
(B) UCSC genome browser view of H3K27ac, H3K4me1, and H3K4me3 ChIP-seq binding density at the Gata4 locus in Spry124fl/fl EV and HRasG12V MEFs.
(C) Relative mRNA levels of HRasG12V and Spry124/ target genes upon treatment of HRasG12V MEFs with control or Gata4 siRNAs.
(D and E) ChIP-qPCR for H3K27ac (D) and H3K4me1 (E) at Ccl2, Sema7a, and Prkcb enhancer (labeled E) and control (labeled C) regions upon treatment of
HRasG12V MEFs with control or Gata4 siRNAs. A schematic of the primer locations is shown in Figures 3A and S6B.
n = 2 for (A) and (B); n = 3 for (C)–(E). In (A) and (B), a representative biological replicate is shown. In (C)–(E), the values depict themean + SDof biological replicates.
The p values were calculated by a two-tailed t test; *p < 0.05.
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Figure 7. HRasG12V-Transformed Cells Are
Sensitive to Prkcb Inhibition
(A) Viability of Spry124fl/fl EV, Spry124fl/fl
HRasG12V, and Spry124/ EV MEFs treated with
DMSO or LY333531.
(B) Colony formation analysis of HRasG12V MEFs
treated with DMSO or LY333531.
n = 3 for (A) and (B). In (A), the values depict the
mean + SD of biological replicates. In (B), a
representative well is shown and quantification
represents counts per field from mean + SD of
biological replicates. The p values were calculated
by a two-tailed t test; *p < 0.05 and fold change >
1.5 (A); *p < 0.05 (B).HRasG12V MEFs would be more sensitive to LY333531, a clini-
cally relevant Prkcb inhibitor also known as ruboxistaurin (Jirou-
sek et al., 1996), than cell lines lacking H3K27ac at the Prkcb lo-
cus. Indeed, HRasG12V MEFs were significantly more sensitive to
doses of LY333531 ranging from 10–15 mM, compared to
Spry124fl/fl EV or Spry124/ EV MEFs (Figures 7A and S7E).
Furthermore, LY333531 treatment significantly reduced the clo-
nogenicity of HRasG12V MEFs (Figure 7B). Collectively, these
data highlight that enhancer signatures can aid in the identifica-
tion of key deregulated chromatin regulators and target genes
that are contributing to the oncogenic phenotypes of
HRasG12V-transformed cells.
DISCUSSION
Epigenetic deregulation and aberrant activation of RTK
signaling pathways drives tumorigenesis. However, the rela-
tionship between unrestrained RTK signaling and chromatin
modifications at cis-regulatory elements remains to be fully
elucidated. In this study, we contrasted the effects of loss of
feedback regulation and oncogenic RTK signaling on changes
in gene expression and enhancer-associated chromatin modi-
fications. We found that Spry loss led to Erk-dependent
changes in gene expression and H3K27ac deposition at en-
hancers of genes with key roles in oncogenesis such as the
Hoxa cluster and Ccl2. We and others previously showed
that Spry loss alters developmental processes such as branch-
ing morphogenesis of organs in response to RTK signaling
(Basson et al., 2005; Edwin et al., 2009). Furthermore,
decreased Spry expression, particularly Spry1 and Spry2, has
been documented in many malignancies, suggesting that it
may play a role in pathogenesis by removing restraints on
RTK signaling (Masoumi-Moghaddam et al., 2014). Our data
suggest that Spry loss and persistent Erk signaling reprograms1310 Cell Reports 12, 1300–1313, August 25, 2015 ª2015 The Authorsenhancer-associated chromatin modifi-
cations to deregulate gene expression.
Using Spry-deficient cells, we aimed to
identify general mechanisms relevant to
oncogenic Ras- and Raf-driven cancers.
Indeed, expression of KRasG12V,
HRasG12V, and BRafV600E led to aberrant
activation and H3K27ac marking at a
subset of Spry124/ targets. Early work
showed that HRasG12V induces a more relaxed chromatin con-
formation (Laitinen et al., 1990), which is consistent with the
increased H3K27ac at enhancers that we observed in response
to oncogenic Ras and Raf. However, our study revealed that the
majority of deregulated target genes, reprogrammed SEs, and
deployed TF networks altered upon HRasG12V transformation
are distinct from those modulated upon Spry loss. This disparity
may result from differences in the strength and duration of Ras-
Erk activation in response to these perturbations. Alternatively,
RTK and non-RTK pathways may be differentially activated in
the contexts of Spry loss and HRasG12V transformation. In accor-
dance with the latter idea, we detected a unique FGF-induced
150- to 185-kDa phosphotyrosine species in Spry-deficient
cells, which may reflect hyperactivation of the FGFR upon Spry
loss. Spry proteins limit signaling at many points downstream
of the RTK pathway, including the activation of Ras and Raf
(Edwin et al., 2009), which may influence the resulting output
of chromatin deregulation and aberrant gene expression. Onco-
genic EGFRL858R and PIK3CAH1047R potently activated Akt but
did not induce changes in the expression or chromatin marking
at enhancers of Spry124/ target genes, suggesting that
EGFRL858R and PIK3CAH1047R regulate distinct subsets of genes
and enhancers. It remains to be determined if aberrant PI3K-AKT
signaling results in global chromatin changes, or whether our ob-
servations are specific to the Ras-ERK axis.
Due to the high frequency ofRASmutations in almost all forms
of cancer and the lack of therapies targeting cancers driven by
oncogenic Ras, the study of this oncogene has become a center-
piece of new basic and translational research efforts (Stephen
et al., 2014). Tumors commonly harbor mutations in both RTK
pathway components and chromatin regulators, and recent
studies indicate that oncogenic Ras signaling mediated by
loss of Nf1 cooperates with disruption chromatin regulators,
including Mll3 and Suz12, to accelerate oncogenesis (Chen
et al., 2014; De Raedt et al., 2014; Kandoth et al., 2013). The BET
bromodomain inhibitor JQ1 is highly efficacious in treating pre-
clinical cancer models driven by aberrant Ras activation,
including non-small cell lung cancer, acute myeloid leukemia,
and malignant peripheral nerve sheath tumors (Chen et al.,
2014; De Raedt et al., 2014; Shimamura et al., 2013). In accor-
dance with these studies, we found that JQ1 treatment
repressed the aberrant transcriptional responses and clonoge-
nicity of HRasG12V-transformed cells. In viability assays, control
cells weremore sensitive to JQ1 treatment than HRasG12V-trans-
formed cells, whichmay be due to the high level of amplified RTK
signaling and redistribution of H3K27ac at key target genes upon
HRasG12V transformation. Combining low doses of PD0325901
with JQ1 was moderately more potent than using each com-
pound alone in HRasG12V-transformed cells. The lack of a more
potent effect when combining these compounds may be due
to their convergence on a shared set of target genes or their
sharp dose-response curves, such that suboptimal doses of
the drugs fail to effectively inhibit gene expression. Investigation
into the functional role of BET bromodomain proteins in onco-
genic Ras-driven cancers will provide further insight into the
mechanisms driving oncogenesis.
H3K27ac enhancer signatures are useful in the identification
of aberrant oncogenic transcriptional programs and classifica-
tion of malignant tissue (Chapuy et al., 2013). HRasG12V SE sig-
natures and TF motif analyses highlighted Gata4 as a candidate
TF promoting the oncogenic HRasG12V program. We demon-
strate that Gata4 is required for the aberrant H3K27ac
enhancer marking and expression changes upon HRasG12V
transformation. Previous studies showed that Gata4 is regu-
lated by post-translational modifications, including phosphory-
lation by kinases downstream of ERK (Liang et al., 2001).
Our data suggest that Gata4 may be a misregulated pioneer
factor downstream of oncogenic HRasG12V, activated through
a feed-forward loop due to aberrant enhancer marking. We
also identified Prkcb as an HRasG12V target susceptible to
chemical inhibition, which promotes the viability and clonoge-
nicity of HRasG12V-transformed cells. One limitation of our
study is that the experiments were performed exclusively in
MEFs. Therefore, further work will be required to evaluate the
functional role of Gata4 and clinical significance of BET bromo-
domain and Prkcb inhibition in oncogenic Ras-driven epithelial
cancers using appropriate cell and mouse models. In sum, our
study shows that examination of histone modification signa-
tures and identification of oncogene-regulated enhancers can
yield insight into the key processes and targets that drive ma-
lignancy. Our data support a model in which unrestrained
RTK signaling modulates gene expression through coordinated
regulation of enhancers.
EXPERIMENTAL PROCEDURES
Cell Lines, Culture Conditions, and FGF Treatment
Spry124fl/fl and Spry124/ MEFs were cultured in DMEM containing 10%
fetal bovine serum (FBS) as previously described (Akbulut et al., 2010). Unsyn-
chronized MEFs were maintained in DMEM containing 10% FBS for 24 hr.
Serum-starved MEFs were maintained in DMEM containing 0.1% FBS for
24 hr. FGF-treated MEFs were maintained in DMEM containing 0.1% FBS
for 20 hr, after which 10 ng/ml FGF (Life Technologies) was directly added toCellthe media for an additional 4 hr, unless otherwise noted. Additional details
related to retroviral transduction, inhibitor treatments, small interfering RNA
transfection, protein and RNA isolation, and biological assays can be found
in the Supplemental Experimental Procedures.
ChIP-qPCR and ChIP-Seq
ChIP experiments for histone modifications were performed as described pre-
viously (Martinez-Garcia et al., 2011). ChIP-seq analyses were performed as
described previously (Love´n et al., 2013). Antibodies, primers, and detailed
ChIP-seq analyses are described in the Supplemental Experimental
Procedures.
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